Harry Jarrett | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr. Harry Jarrett | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Head of Science and Research at Heights, United Kingdom

Dr. Harry Jarrett is a passionate scientist with a focus on nutritional research, particularly in the context of chronic disease prevention. He believes that optimizing nutrition can significantly reduce the risk of prevalent health issues. With a PhD in Nutritional Sciences from Ulster University and a strong academic background, Dr. Jarrett has combined clinical and research expertise to contribute to the field of nutrition. His work spans various roles, including his current position as Head of Science and Research at Heights, where he leads human intervention trials and drives product development. Additionally, Dr. Jarrett has substantial experience in the medical field, including his work as a COVID-19 Research Laboratory Coordinator during the pandemic. His career is a testament to his commitment to advancing nutrition science and its real-world applications, striving to make significant contributions to improving public health through research and innovation.

Professional Profile

Education

Dr. Jarrett completed his PhD in Nutritional Sciences at the Nutrition Innovation Centre for Food and Health at Ulster University, where he focused on gene-environment interactions in blood pressure and stroke risk. His thesis investigated how riboflavin can lower systolic blood pressure, a significant finding in hypertension research. Prior to his PhD, he earned a Master’s degree in Exercise and Health Sciences from the University of Exeter, with a focus on nutrition’s impact on mental health and neurodegenerative diseases. Dr. Jarrett also completed a Bachelor’s degree in Exercise and Sport Sciences from the University of Exeter, graduating with first-class honors. His academic journey has been marked by strong achievements, including a postgraduate scholarship, distinction profile, and recognition for his contributions to research. Throughout his education, Dr. Jarrett has demonstrated a deep commitment to exploring the intersections between nutrition, health, and disease prevention.

Professional Experience

Dr. Jarrett’s professional experience spans several prestigious institutions and roles. Currently, he serves as Head of Science and Research at Heights, where he is responsible for the strategic direction and execution of research projects, including human intervention trials focused on nutrition and health. He also coordinates the translation of scientific findings into products and marketing strategies. From 2021 to 2024, Dr. Jarrett worked as a COVID-19 Research Laboratory Coordinator at Guy’s and St Thomas’ NHS Trust, where he managed clinical trials during the pandemic and was responsible for writing protocols, securing ethical approvals, and overseeing research quality. He also held a postdoctoral position at the NNEdPro Global Institute for Food and Nutrition Research, where he led investigations into cardiovascular disease risk factors using data from the UK Biobank. Additionally, Dr. Jarrett has contributed to academia by mentoring students and delivering lectures on nutrition and B-vitamin biochemistry.

Research Interests

Dr. Jarrett’s primary research interest lies in the relationship between nutrition and chronic disease prevention, with a particular focus on cardiovascular health and blood pressure regulation. His work has explored how micronutrients, especially B-vitamins like riboflavin, can impact blood pressure and metabolic function, offering new avenues for non-pharmacological interventions. His PhD research focused on understanding gene-environment interactions, specifically how certain genetic variations can influence an individual’s response to nutritional interventions. Dr. Jarrett is also interested in how nutrition can mitigate the effects of age-related diseases, including neurodegenerative conditions and mental health disorders. His ongoing research involves human intervention trials to assess the efficacy of nutritional supplements in improving health outcomes. Additionally, he is involved in investigating large datasets, such as those from the UK Biobank, to uncover insights into the broader epidemiological relationships between diet and health.

Awards and Honors

Dr. Harry Jarrett has received numerous accolades throughout his academic and professional career, reflecting his exceptional research contributions. Notably, he was awarded the Best Poster award at the Federation of American Societies for Experimental Biology (FASEB) conference for his work on folic acid and one-carbon metabolism. He also earned the Broadening Horizons Travel Bursary from Ulster University and a top-ranking young investigator abstract at the British and Irish Hypertension Society conference. Dr. Jarrett’s commitment to research excellence has earned him recognition from his peers and colleagues. His PhD research, published in the American Journal of Clinical Nutrition, has been widely cited and demonstrates his capacity to contribute to significant scientific advancements. Additionally, he has received honors such as the Postgraduate Commendation from the University of Exeter, further acknowledging his academic excellence and dedication to the field of nutrition science.

Conclusion

Dr. Harry Jarrett is a well-rounded and accomplished researcher with a clear impact in the field of nutrition science. His combination of robust academic background, hands-on clinical experience, leadership in research, and commitment to advancing public health makes him a highly suitable candidate for the Best Researcher Award. By enhancing his cross-disciplinary collaborations and expanding the visibility of his research, Dr. Jarrett has the potential to make even greater contributions to the field in the future.

Publications Top Noted

  • The Role of the Gut Microbiome and Probiotics in Sports Performance: A Narrative Review Update

    • Author(s): Harry Jarrett, Sophie Medlin, James C. Morehen
    • Year: 2025
    • Citation: Jarrett H, Medlin S, Morehen JC. The Role of the Gut Microbiome and Probiotics in Sports Performance: A Narrative Review Update. Nutrients. 2025;17(4):690. doi: 10.3390/nu17040690.
  • Survival of Probiotic Bacterial Cells in the Upper Gastrointestinal Tract and the Effect of the Surviving Population on the Colonic Microbial Community Activity and Composition

    • Author(s): Marlies Govaert, Chloë Rotsaert, Chelsea Vannieuwenhuyse, Cindy Duysburgh, Sophie Medlin, Massimo Marzorati, Harry Jarrett
    • Year: 2024
    • Citation: Govaert M, Rotsaert C, Vannieuwenhuyse C, Duysburgh C, Medlin S, Marzorati M, Jarrett H. Survival of Probiotic Bacterial Cells in the Upper Gastrointestinal Tract and the Effect of the Surviving Population on the Colonic Microbial Community Activity and Composition. Nutrients. 2024;16(8):2791. doi: 10.3390/nu16162791.
  • Magnesium in Human Health and Disease: A Review of Our Current Understanding

    • Author(s): Harry Jarrett, Ryan McNally, Anna Hernández-Rubio, Sally Brett, Luca Faconti
    • Year: 2024
    • Citation: Jarrett H, McNally R, Hernández-Rubio A, Brett S, Faconti L. Magnesium in Human Health and Disease: A Review of Our Current Understanding. EC Nutrition. 2024;23(7):2303-2315.
  • Association of dietary flavan-3-ol intakes with plasma phenyl-γ-valerolactones: analysis from the TUDA cohort of healthy older adults

    • Author(s): Donato Angelino, Aoife Caffrey, Helene McNulty, Chris IR. Gill, Pedro Mena, Alice Rosi, Katie Moore, Leane Hoey, Michelle Clements, Eamon Laird, et al.
    • Year: 2023
    • Citation: Angelino D, Caffrey A, McNulty H, Gill CIR, Mena P, Rosi A, Moore K, Hoey L, Clements M, Laird E, et al. Association of dietary flavan-3-ol intakes with plasma phenyl-γ-valerolactones: analysis from the TUDA cohort of healthy older adults. Am J Clin Nutr. 2023;118(2):426-438. doi: 10.1016/j.ajcnut.2023.06.006.
  • Vitamin B-6 and riboflavin, their metabolic interaction, and relationship with MTHFR genotype in adults aged 18-102 years

    • Author(s): Harry Jarrett, Helene McNulty, Catherine Hughes, Kristina Pentieva, James J. Strain, Anne Molloy, Aileen McCann, et al.
    • Year: 2022
    • Citation: Jarrett H, McNulty H, Hughes CF, Pentieva K, Strain JJ, Molloy A, McCann A, et al. Vitamin B-6 and riboflavin, their metabolic interaction, and relationship with MTHFR genotype in adults aged 18-102 years. Am J Clin Nutr. 2022;116(6):1422-1431. doi: 10.1093/ajcn/nqac240.
  • Validity of plasma phenyl-γ-valerolactones as novel biomarkers of dietary (poly)phenols: Preliminary analysis from the VALID project

    • Author(s): B. Parmenter, K. Moore, D. Angelino, D. Del Rio, H. McNulty, A.M. Molloy, C. Cunningham, M. Ward, B. Pucci, H. Jarrett, et al.
    • Year: 2018
    • Citation: Parmenter B, Moore K, Angelino D, Del Rio D, McNulty H, Molloy AM, Cunningham C, Ward M, Pucci B, Jarrett H, et al. Validity of plasma phenyl-γ-valerolactones as novel biomarkers of dietary (poly)phenols: Preliminary analysis from the VALID project. Proc Nutr Soc. 2018;77(3):234-243. doi: 10.1017/s0029665118001040.
  • Blood pressure and hypertension in relation to cognitive performance in older Irish adults from the TUDA cohort: Preliminary analysis

    • Author(s): Harry Jarrett
    • Year: 2018
    • Citation: Jarrett H. Blood pressure and hypertension in relation to cognitive performance in older Irish adults from the TUDA cohort: Preliminary analysis. J Hum Hypertens. 2018;32(5):319-326. doi: 10.1038/s41371-018-0089-5.
  • Effect of B-vitamin Supplementation on Cognitive Performance and Brain Function in The BrainHOP Trial

    • Author(s): Katie Moore, Catherine Hughes, Kirsty Porter, Leanne Doherty, Pramod Gaur, Fergal Tracey, Maurice O’Kane, Harry Jarrett, Mary Ward, Leanne Hoey
    • Year: 2018
    • Citation: Moore K, Hughes C, Porter K, Doherty L, Gaur P, Tracey F, O’Kane M, Jarrett H, Ward M, Hoey L. Effect of B-vitamin Supplementation on Cognitive Performance and Brain Function in The BrainHOP Trial. Age Ageing. 2018;47(5):702-710. doi: 10.1093/ageing/afy141.35.

 

Irving Lara | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr. Irving Lara | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Research assistant at Centro de Investigación Biomédica de Occidente, Mexico

Dr. Irving Jair Lara Navarro is a Mexican researcher specializing in genetics and molecular biology. Born on December 9, 1990, in Guadalajara, Jalisco, he has dedicated his career to advancing genetic research, particularly in gene therapy. His work integrates molecular diagnostics, biotechnology, and clinical applications, making significant contributions to biomedical sciences. With a passion for teaching and research, he has been actively involved in academia and laboratory settings, working to bridge the gap between fundamental genetics and medical applications. Dr. Lara Navarro has played a key role in developing innovative approaches for genetic modification, particularly using CRISPR/Cas9 technology. His expertise extends to epidemiological surveillance, laboratory diagnostics, and academic instruction. Throughout his career, he has collaborated with various research institutions, healthcare professionals, and academic institutions, fostering a multidisciplinary approach to genetics. His commitment to scientific excellence and education continues to drive his contributions to the field.

Professional Profile

Education

Dr. Irving Jair Lara Navarro pursued his academic journey in biological sciences, earning a Bachelor’s degree in Biology from the University of Guadalajara (CUCBA) in 2014. His undergraduate research focused on optimizing transduction conditions in keratinocytes using lentiviral vectors. Continuing his passion for genetics, he pursued a Doctorate in Human Genetics at the University of Guadalajara (CUCS), completing it in 2024. His doctoral research revolved around gene therapy using CRISPR/Cas9 technology for modifying the F9 gene in human mesenchymal cells, aiming to enhance the production of Factor IX, a crucial protein for blood clotting. This work has potential therapeutic applications, particularly in treating hemophilia. His academic training has provided him with expertise in molecular biology, genetic engineering, and biomedical research. His strong foundation in experimental design and genetic modifications has positioned him as a key researcher in the field of gene therapy and molecular medicine.

Professional Experience

Dr. Lara Navarro has gained extensive professional experience in research and academia. From 2020 to 2021, he worked as a Research Technician at the Mexican Institute of Social Security (IMSS), contributing to nucleic acid extraction and molecular diagnostics in epidemiological surveillance. He later joined Laboratorio Biodiagnóstica in 2021, where he worked as a Molecular Biology Laboratory Technician, managing laboratory operations, coordinating research teams, and implementing molecular analysis techniques. In addition to his laboratory roles, he has been actively involved in teaching. He served as an Adjunct Professor at Tecmilenio University (Zapopan) from 2021 to 2022, teaching basic sciences at the high school level. Since 2023, he has been a faculty member at Universidad Guadalajara Lamar, where he teaches genetics and biomolecular sciences to medical students. His combined experience in laboratory research and academia has strengthened his ability to contribute to both scientific discovery and education.

Research Interests

Dr. Lara Navarro’s primary research interests lie in genetic engineering, molecular biology, and gene therapy. His doctoral research on CRISPR/Cas9-based gene modification for Factor IX production highlights his focus on therapeutic applications of molecular genetics. He is particularly interested in genetic therapies for hematological disorders, biotechnology applications in medicine, and the development of precision medicine approaches. His expertise in nucleic acid manipulation and viral vector systems contributes to advancements in personalized genetic treatments. Additionally, he has a keen interest in molecular diagnostics and epidemiological surveillance, particularly in developing genetic testing methodologies for disease prevention and treatment. As a researcher, he aims to explore the potential of stem cell therapy, regenerative medicine, and CRISPR-based genome editing for clinical applications. His work aims to bridge the gap between fundamental genetic research and practical medical solutions, contributing to cutting-edge advancements in biomedical sciences.

Awards and Honors

While Dr. Lara Navarro has demonstrated exceptional expertise in genetics and molecular biology, his professional journey is still evolving in terms of formal recognitions. His research in CRISPR/Cas9 gene therapy holds significant potential for future awards and funding opportunities. As an emerging scientist, he has been recognized for his contributions to molecular diagnostics and epidemiological research at IMSS, where he played a crucial role in laboratory procedures during the COVID-19 pandemic. His involvement in academia and research has earned him respect within the scientific and medical communities. While he may not yet have received high-profile research awards, his work on genetic modifications and biomedical applications positions him as a strong candidate for future honors in genetics, biotechnology, and medical research. With continued research output and publications, he is likely to receive formal recognition for his contributions to the field of genetic engineering and molecular medicine.

Conclusion

Dr. Irving Jair Lara Navarro has a strong foundation in genetics, molecular biology, and research methodologies, making him a promising candidate. However, to be a strong contender for the Best Researcher Award, he should focus on publishing in high-impact journals, securing research funding, and increasing international recognition. If these aspects are addressed, he would be a more competitive candidate for the award.

Publications Top Noted

  • CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy
    • Authors: Lara-Navarro, I.J., Jave-Suárez, L.F., Marchal, J.A., Jaloma-Cruz, A.R.
    • Year: 2024
    • Journal: Life
    • Citations: 0
  • Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives
    • Authors: Lara-Navarro, I.J., Jaloma-Cruz, A.R.
    • Year: 2022
    • Journal: Tohoku Journal of Experimental Medicine
    • Citations: 3
  • Genetic analysis for carrier diagnosis in hemophilia A and B in the Mexican population: 25 years of experience
    • Authors: González-Ramos, I.-A., Mantilla-Capacho, J.-M., Luna-Záizar, H., Evangelista-Castro, N., Jaloma-Cruz, A.R.
    • Year: 2020
    • Journal: American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
    • Citations: 5
  • Molecular thrombophilic profile in Mexican patients with idiopathic recurrent pregnancy loss
    • Authors: López-Jiménez, J.J., Porras-Dorantes, Á., Juárez-Vázquez, C.I., Lara-Navarro, I.J., Jaloma-Cruz, A.R.
    • Year: 2016
    • Journal: Genetics and Molecular Research
    • Citations: 19
  • Two girls with a de novo Xq rearrangement of paternal origin: T(X;9)(q24;q12) or rea(X)dup q
    • Authors: Vásquez-Velásquez, A.I., Rivera, H., Castro, A.G., Mendoza-Pérez, P., García-Ortiz, J.E.
    • Year: 2016
    • Journal: Taiwanese Journal of Obstetrics and Gynecology
    • Citations: 0
  • A further inv dup/del 9p de novo rearrangement. Reappraisal of 25 instances
    • Authors: Lara-Navarro, I.J., Córdova-Fletes, C., García-Ruiz, A., Rivera, H.
    • Year: 2015
    • Journal: Gene Reports
    • Citations: 0